Clinical Trials Browser

Phase 2 × Plasmablastic Lymphoma × belantamab mafodotin × Clear all

NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Phase 2 Terminated

10 enrolled 11 charts

Plasmablastic Lymphoma